pubs.acs.org/joc

Synthesis of Branched Monodisperse Oligoethylene Glycols and ¹⁹F MRI-Traceable Biomaterials through Reductive Dimerization of Azides

Jing Zhang, Yuan Yuan, Yu Li, Hao Yang, Huaibin Zhang, Shizhen Chen, Xin Zhou, Zhigang Yang,* and Zhong-Xing Jiang*



However, the tedious synthesis limited their availability and application. We herein present an azide reductive dimerization method for the convenient synthesis of aza-M-OEGs and derivatives, which provides easy access to a variety of multifunctionalized and branched M-OEGs in

one step. With this method, hexa-arm M-OEGs with 54 symmetrical fluorines were synthesized in two steps as a water-soluble, selfassemble, ¹⁹F MRI sensitive, and biocompatible dendritic biomaterial.

K = H, Me, C(CF₃)₃

n = 4, 6, 8

Polyethylene glycols (PEGs) are the most used polymers in biomedicine, while the introduction of PEGs to targets (PEGvlation) has become one of the most successful drug development strategies in the pharmaceutical industry.¹ Until 2017, 17 PEGylated drugs had been approved by the U.S. FDA (data from www.fda.gov). In biomedicine, PEGs above 4000 Da are mainly used as PEGylation agents for biomacromolecules, while PEGs below 4000 Da, more appropriately named as oligoethylene glycols (OEGs), are extensively used as PEGylation agents, formulation additives, water-soluble and biocompatible linkers and scaffolds in nanomedicine, drug conjugates, probes, etc. The biomedical impact of PEGylation lies in the so-called "stealth" effects of PEGs, which has been regarded as the "gold-standard" for biopolymers. With the "stealth" effects, the PEGylated targets usually exhibit increased solubility and stability, reduced immunogenicity and dosing frequency, and optimized pharmacokinetics.²

Although the first PEGylated drug was approved in 1990, two major issues still compromise PEGs' biomedical application. First, as complex mixtures of homologues, the heterogeneity issue of polydisperse PEGs leads to many difficulties in PEGylation, purification, characterization, clinical application, and drug regulatory approval.³ Although many synthetic strategies to monodisperse PEGs (M-PEGs) have recently been developed⁴ and many benefits of M-PEGs have been clearly demonstrated,⁵ polydisperse PEGs are still overwhelmingly used in biomedicine. Second, as linear polymers with only two functional terminals, the synthesis of multifunctionalized PEGs and multiarm PEGs requires long synthesis and tedious purification, which results in their low synthetic efficacy and high prices. Multifunctionalized PEGs are highly valuable linkers and scaffolds in biomedicine, while multiarm PEGs have multivalence effects and superior "stealth"

effects than their linear counterparts.⁶ Therefore, the development of effective and scalable synthetic strategies for monodisperse, multifunctionalized, and multiarm PEGs will not only address many long-lasting issues in PEGs but also greatly promote their biomedical applications.

As the amide bond is widely used in bioconjugation due to its easy formation, biodegradability, and biocompatibility, modification of PEGs into amines or acids has become a routing strategy to functionalize PEGs. A macrocyclic sulfate (MCS) strategy for convenient mono- and dual-functionalization of M-OEGs with an amino or azide group was developed in this group,⁷ which led to many multifunctional "smart" biomaterials.⁸ Recently, an unexpected side product was isolated when we hydrogenated octaethylene glycol monoazide into the corresponding amine, in which the azide was reduced and dimerized into a secondary amine, aza-M-OEG, with three functional groups (Scheme 1). Although reductive dimerization reactions of azides were reported by Ahn and Undheim, respectively,9 it has not been fully investigated on OEGs azides.¹⁰ Herein, we explored the reductive dimerization reaction on M-OEG monoazides and employed it as a convenient and scalable strategy to aza-M-OEGs, multifunctionalized, and multiarm M-OEGs (Scheme 1). Nucleophilic ring-opening of M-OEG MCS would conveniently afford the starting materials, M-OEG monoazides, from which

Received: February 9, 2020 Published: April 27, 2020




Note

CH₂CH₂O]

Y = H, RCO, ROCO

(28 examples)

Scheme 1. Synthesis of Multifunctionalized and Multiarm M-OEGs through Reductive Dimerization



multifunctionalized aza-M-OEGs and derivatives could be prepared in one step. Further, the aza-M-OEGs could be conveniently transformed into multiarm M-OEGs in one step, of which fluorinated dendrimers, hexa-arm M-OEGs with 54 symmetrical fluorines, were designed as F-19 magnetic resonance imaging (¹⁹F MRI)-traceable biomaterials.

With the ideas in mind, the M-OEG monoazides were first prepared on multigram scales (Scheme 2). Through the

```
Scheme 2. Synthesis of M-OEG Monoazides 2-4 and 7-11
```

```
NaX or NaH + HX, DMF,
                                 then H<sub>2</sub>SO<sub>4</sub>, H<sub>2</sub>O, THF
                                                                          X[CH<sub>2</sub>CH<sub>2</sub>O]<sub>n</sub>H
                           NaX = NaN_3
                                                                           2. n = 4. 79%
                           HX = H[OCH_2CH_2]_2N_3
                                                                          3, n = 6, 83%
                           HX = H[OCH_2CH_2]_4N_3
                                                                          4 n = 8 85\%
                           NaX = NaOC(CF_3)_3
                                                                           5, n = 4, 89%
                           \mathsf{HX} = \mathsf{H}[\mathsf{OCH}_2\mathsf{CH}_2]_4\mathsf{OC}(\mathsf{CF}_3)_3
                                                                          6, n = 8, 80%
             CH<sub>3</sub>I, NaH, THF
                                       N<sub>3</sub>[CH<sub>2</sub>CH<sub>2</sub>O]<sub>n</sub>Me
2.3.4
                                         7, n = 4, 99%
                                         8, n = 6, 87%
                                         9, n = 8, 94%
        TosCl, NaOH(aq), then
           NaN<sub>3</sub>, DMF, 80 °C
56
                                              N<sub>3</sub>[CH<sub>2</sub>CH<sub>2</sub>O]<sub>n</sub>C(CF<sub>3</sub>)<sub>3</sub>
                                                  10 n = 4 70%
                                                  11, n = 8, 71%
```

nucleophilic ring-opening of tetraethylene glycol MCS 1, a series of monofunctionalized M-OEGs 2-6 were obtained, including M-OEGs monoazides 2-4, which were further transformed into methylated M-OEGs monoazides 7-9 and perfluoro-*tert*-butylated M-OEGs monoazides 10 and 11 with high efficacy.

Then, octaethylene glycol monoazide 4 was employed as the model substrate to optimize the reductive dimerization conditions. First, with methanol as a solvent and 1 atm of hydrogen gas as an H-source, easily available palladium on carbon (Pd/C) was identified from a panel of palladium catalysts as the most effective catalyst for the reaction, including $PdCl_2(PPh_3)_2$, $PdCl_2$, $Pd(dba)_2$, $Pd(PPh_3)_4$, Pd-(AcO)₂, $Pd(OH)_2/C$, and Pd/C (Table 1, entries 1–7).

Table 1. Reaction Conditions Optimization^a

	N ₃ [CH ₂ CH ₂ O] ₈	H-source, catalyst, solvent	[CH ₂ (CH₂O] ₈ H
	4		`[CH ₂ 0	CH ₂ O] ₈ H 2
entry	catalyst	H-source	solvent	yield % ^b (yield % ^c)
1	PdCl ₂ (PPh ₃) ₂	H_2	MeOH	
2	PdCl ₂	H_2	MeOH	28 (56)
3	$Pd(dba)_2$	H_2	MeOH	37 (81)
4	$Pd(PPh_3)_4$	H ₂	MeOH	22 (64)
5	$Pd(AcO)_2$	H ₂	MeOH	15 (32)
6	$Pd(OH)_2/C$	H ₂	MeOH	18 (72)
7	Pd/C	H ₂	MeOH	95
8	Pd/C	$N_2H_4 \cdot H_2O$	MeOH	
9	Pd/C	НСООН	MeOH	
10	Pd/C	HEH	MeOH	
11	Pd/C	H ₂	EtOH	55 (14)
12	Pd/C	H ₂	iPrOH	63 (30)
13	Pd/C	H ₂	THF	
14	Pd/C	H ₂	CH ₃ CN	
15	Pd/C	H ₂	DCM	
16	Pd/C	H ₂	acetone	
17	Pd/C	H ₂	HCO_2H	
18 ^d	Pd/C	H ₂	MeOH	82
19 ^e	Pd/C	H ₂	MeOH	65
20 ^f	Pd/C	H_2	MeOH	88 (17)
21 ^g	Pd/C	H ₂	MeOH	32 (48)
22 ^h	Pd/C	H ₂	MeOH	23 (16)
23 ⁱ	Pd/C	H_2	MeOH	71 (14)
a .		-		/

^{*a*}Unless otherwise noted, the reactions were carried out with 4 (0.05 mmol) and a catalyst (0.01 mmol) in 1.0 mL of solvent at rt for 12 h under a H₂ atmosphere. ^{*b*}Determined by ¹H NMR analysis using 1,3,5-trimethoxybenzene as the internal standard. ^{*c*}The yield of the corresponding primary amine of compound 12. ^{*d*}Reaction proceeded in 0.02 M. ^{*c*}Reaction proceeded in 0.01 M. ^{*f*}Reaction performed at 45 °C. ^{*g*}Reaction performed at 0 °C. ^{*h*}Reaction proceeded for 1 h. ^{*i*}Reaction proceeded for 6 h.

Under the conditions, aza-M-OEGs 12 was obtained with a high ¹H NMR yield of 95%. Second, no aza-M-OEGs 12 was detected when other hydrogen sources were used, including N_2H_4 · H_2O , Hantzsch ester (HEH), and HCOOH (Table 1, entries 8–10). Third, alcohols, especially methanol, were identified as the solvent of choice for the reaction (Table 1, entries 11–17). No aza-M-OEGs 12 was detected when the reaction was carried out in THF, CH₃CN, DCM, acetone, or HCO₂H. Finally, many fine-tunings of the reaction conditions, such as adjusting the substrate concentration, reaction temperature, and time, to further improve the yield of aza-M-OEGs 12 turned out to be unsuccessful (Table 1, entries 18–23).

Under the optimized reaction conditions, the substrate scope of this reaction was explored (Scheme 3). The functional groups (OH, OMe, and $OC(CF_3)_3$) on the other terminal of M-OEG monoazides 2–4 and 7–11 showed little influence on the yields. It is probably because they were too far away from


Scheme 3. Reductive Dimerization of M-OEG Monoazides to aza-M-OEGs

$N_3[CH_2CH_2O]_n X \xrightarrow{H_2, Pd/C, MeOH}$	[CH ₂ CH ₂ O] _n X HN [CH ₂ CH ₂ O] _n X
2 , n = 4, X = H	13 , n = 4, X = H, 71%
3 , n = 6, X = H	14 , n = 6, X = H, 80%
4 , n = 8, X = H	12 , n = 8, X = H, 71%
7 , n = 4, X = Me	15 , n = 4, X = Me, 73%
8 , n = 6, X = Me	16 , n = 6, X = Me, 85%
9 , n = 8, X = Me	17 , n = 8, X = Me, 69%
10 , n = 4, X = C(CF ₃) ₃	18 , n = 4, X = C(CF ₃) ₃ , 71%
11 , n = 8, X = C(CF ₃) ₃	19 , n = 8, X = C(CF ₃) ₃ , 79%

the azide reaction center to exert their electronic and steric effects during this reaction. Due to the same reason, the size of M-OEGs (n = 4, 6, and 8) had little impact on the yield. On 0.5 mmol scales, aza-M-OEGs **12–19** with a variety of M-OEG sizes (n = 4, 6, 8) and terminal groups (X = OH, OMe, and OC(CF₃)₃) were prepared from a panel of M-OEG monoazides with good isolate yields.

With the reductive dimerization strategy, a variety of functionalized aza-M-OEGs were conveniently prepared (Scheme 4). First, the aza-M-OEGs 12-17 are valuable branched M-PEGylation agents for carboxylic group-containing targets, which could simultaneously introduce two M-OEG chains into targets through a biocompatible and biodegradable amide bond. To carry the chemistry one step further, easily available M-OEG monoazides 7-9 were employed to M-

Scheme 4. Synthesis of Functionalized and Multiarm M-OEGs through Reductive Dimerization–Amidation of M-OEG Monoazides




pubs.acs.org/joc

PEGylate an acyl chloride, BzCl, through *in situ* reductive dimerization—amidation, which provided M-OEG amides 20-22 in one step with good yields. Second, through *in situ* reductive dimerization—amidation, aza-M-OEGs-containing acids 23-25 were conveniently prepared as branched M-PEGylation agents for amines and alcohols. Third, the newly formed secondary amines in the reductive dimerization were *in situ* protected with CbzCl to give amides 26-31, which facilitated the further transformation of amides 26-31 into multifunctionalized M-OEGs. Finally, hexa-arm M-OEGs 32 and 33 were conveniently prepared as M-OEG "stars" through the *in situ* reductive dimerization—amidation.

As a promising imaging technology in biomedicine, ¹⁹F MRI provides *in vivo* images without background signals, tissue depth limit, and ionizing radiation. By taking advantage of M-OEGs' high biocompatibility and solubility, many fluorinated M-OEG dendrimers have been developed as novel biomaterials for ¹⁹F MRI-guided drug therapy in this group.⁸ With the reductive dimerization strategy, many valuable building blocks for the rapid construction of ¹⁹F MRI-traceable biomaterials were conveniently prepared, including amines **18** and **19**, acids **34**, **35**, and amides **36–39** (Scheme 5). Recently, perfluoro-

Scheme 5. Synthesis of ¹⁹F MRI-Traceable Biomaterials and Their Building Blocks



tert-butylated amphiphilic M-PEG dendrimers were found to self-assemble onto nanoparticles and transform them into ¹⁹F MRI-traceable theranostics.^{8b-d} Therefore, hexa-arm M-PEGs **40** and **41** with 6 perfluoro-*tert*-butyl groups were conveniently prepared as self-assemble and ¹⁹F MRI-traceable amphiphilic M-OEG dendrimers in one step with a high yield, respectively.

Finally, the physicochemical and biologic potential of M-OEG dendrimers 40 and 41 as ¹⁹F MRI-traceable biomaterials were investigated. First, the lipophilicity of dendrimers 40 and 41 was evaluated by *n*-octanol/water partition coefficients, logP, and measurements (Figure 1a). Dendrimer 41 with octaethylene glycol moieties showed dramatically higher




Figure 1. (a) *n*-Octanol/water partition coefficients logP, (b) solventdependent ¹⁹F NMR, (c) DLS, (d) *in vitro* ¹⁹F MRI, (e, f) and cell viability assay of M-OEG dendrimers 40 and 41.

hydrophilicity than dendrimer 40 with tetraethylene glycol moieties (logP: 0.784 versus 1.939). Accordingly, dendrimer 41 was soluble in water, while dendrimer 40 was hardly soluble in water. Second, the self-assembly behavior of dendrimers 40 and 41 was investigated with the solvent-dependent ¹⁹F NMR (Figure 1b, from 100% methanol to 100% D_2O), in which the chemical shift changes and peak broadening indicated their self-assembly in D_2O . Further, dynamic light scattering (DLS) of dendrimer 41 solution indicated that dendrimer 41 selfassembled into highly homogenized nanoparticles with a diameter of 116 nm and a super low polydispersity (PDI) of 0.019 (Figure 1c). The particle size and PDI are in the optimal range of nanomedicines. Third, ¹⁹F MRI sensitivity of dendrimers 40 and 41 was evaluated by in vitro ¹⁹F MRI experiments (Figure 1d). With 54 symmetric fluorines and a united ¹⁹F NMR signal, dendrimers 40 and 41 exhibited high ¹⁹F MRI sensitivity, which were detected at a low concentration of 0.23 mM with a short scan time of 160 s. Fourth, the biocompatibility of dendrimers 40 and 41 was evaluated by the cell viability assay (Figure 1e,f). To provide in vitro data for the future in vivo 19F MRI study in a HepG2 human liver cancer xenograft mouse model, HepG2 cells and mouse fibroblast L929 cells were chosen for the cell viability assay. High biocompatibility of dendrimers 40 and 41 was observed, while 41 exhibited even higher biocompatibility than 40 due to its higher M-OEG content. Therefore, hexa-arm M-OEG 41 was identified as a promising ¹⁹F MRI-traceable biomaterial with high solubility, self-assembly ability, ¹⁹F MRI sensitivity, and biocompatibility.

In conclusion, we have explored the reductive dimerization of M-OEG monoazides and developed a convenient and practical strategy to a series of valuable aza-M-OEGs in biomedicine, including M-PEGylation agents, multifunctionalized, and highly branched M-OEGs. The mild reaction conditions and convenient *in situ* process facilitated the convenient preparation of a broad range of valuable aza-M- OEG derivatives. Based on the chemistry, a water-soluble, selfassemble, ¹⁹F MRI sensitive, and biocompatible hexa-arm M-OEG dendrimer was conveniently prepared in two steps as a high-performance ¹⁹F MRI-traceable biomaterial. In an era of accurate medicine, although the drawbacks of polydisperse PEGs are obvious, M-PEGs have not received a broad application in biomedicine due to their synthetic difficulty and limited availability. Our M-OEG monoazides reductive dimerization-amidation strategy and M-OEG macrocyclic sulfates ring-opening strategy significantly simplified the multifunctionalized and multiarm M-OEGs synthesis, which would greatly promote the application of M-PEGs in biomedicine and transform PEGylation into a reliable and quantitative science. The application of the hexa-arm M-OEG dendrimer as ¹⁹F MRI-traceable drug delivery vehicles is currently in progress and will be published in due course.

EXPERIMENTAL SECTION

Preparation of Monofunctionalized M-QEG 2-6. 2-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)ethan-1-ol (2).^{7a,11a} To a solution of cyclic sulfate 1 (prepared according to the procedures, ^{7a} 20.0 g, 78.0 mmol) in DMF (200 mL) was added NaN₃ (6.6 g, 101.5 mmol), and the resulting mixture was stirred at 80 °C overnight. After the mixture was cooled to room temperature, excess NaN₃ was filtered by a pad of Celite. DMF was removed under a vacuum, and the resulting residue was dissolved in THF (150 mL). Then, water (2.8 mL) was added, and H₂SO₄ was added to adjust the pH to 3.0. The mixture was stirred until hydrolysis was completed. The reaction mixture was neutralized with saturated NaHCO₃ solution, concentrated under a vacuum, and purified by flash chromatography on silica gel with ethyl acetate/petroleum ether (1:1) as eluents to obtain compound 2 as a clear oil (13.5 g, 79% yield). ¹H NMR (400 MHz, CDCl₃): δ 3.74-3.71 (m, 2H), 3.69–3.67 (m, 10H), 3.63–3.60 (m, 2H), 3.41 (t, J = 5.0 Hz, 2H).

17-Azido-3,6,9,12,15-pentaoxaheptadecan-1-ol (3).¹⁰ Compound 3 was obtained from compound 1 as a light yellow oil in 83% yield by employing the same synthetic procedures as compound 2. (Compound 3 was purified by silica gel column chromatography (ethyl acetate/petroleum ether = 1:1) as a light yellow oil in 83% yield (12.0 g) by employing the same synthetic procedures as compound 2.) ¹H NMR (400 MHz, CDCl₃): δ 3.66–3.59 (m, 20H), 3.54–3.52 (m, 2H), 3.32 (t, J = 5.0 Hz, 2H).

23-Azido-3,6,9,12,15,18,21-heptaoxatricosan-1-ol (4).^{11a} Compound 4 was obtained from compound 1 as a light yellow oil in 85% yield by employing the same synthetic procedures as compound 2. (Compound 4 was purified by silica gel column chromatography (MeOH/DCM = 1:60) as a light yellow oil in 85% yield (5.48 g) by employing the same synthetic procedures as compound 2.) ¹H NMR (400 MHz, CDCl₃): δ 3.74–3.71 (m, 2H), 3.69–3.66 (m, 26H), 3.62–3.60 (m, 2H), 3.41–3.38 (m, 2H).

14,14,14-Trifluoro-13,13-bis(trifluoromethyl)-3,6,9, 12-tetraoxatetradecan-1-ol (5).^{7a} Compound 5 was obtained from compound 1 as a light yellow oil in 89% yield by employing the same synthetic procedures as compound 2. (Compound 5 was purified by silica gel column chromatography (ethyl acetate/petroleum ether = 1:2) as a light yellow oil in 89% yield (5.60 g) by employing the same synthetic procedures as compound 2.) ¹H NMR (500 MHz, CDCl₃): δ 4.16 (t, J = 4.8 Hz, 2H), 3.75–3.72 (m, 4H), 3.70–3.65 (m, 8H), 3.62–3.60 (m, 2H).

26,26,26-Trifluoro-25,25-bis(trifluoromethyl)-3,6,9, 12,15,18,21,24-octaoxahexacosan-1-ol (6). Compound 6 was obtained from compound 1 as a light yellow oil in 80% yield by employing the same synthetic procedures as compound 2. (Compound 6 was purified by silica gel column chromatography (ethyl acetate/petroleum ether = 1:1) as a light yellow oil in 80% yield (6.32 g) by employing the same synthetic procedures as compound 2.) ¹H NMR (400 MHz, CDCl₃): δ 4.16 (t, J = 4.9 Hz, 2H), 3.75–3.71 (m, 4H), 3.69–3.60 (m, 26H). ¹³C NMR (126 MHz, CDCl₃): δ 120.3 (q, *J* = 293.6 Hz), 79.7 (dd, *J* = 60.5, 30.2 Hz), 72.5, 71.7, 71.0, 70.57, 70.55, 70.53, 70.51, 70.50, 70.49, 70.47, 70.3, 69.3, 69.2, 67.0, 61.6. HRMS (ESI) *m/z*: [M + Na]⁺ calcd for C₂₀H₃₃F₉NaO₉⁺: 611.1873; found, 611.1864.

Preparation of M-OEG Monoazides 7–9. *13-Azido-2,5,8,11tetraoxatridecane (7).*^{11b} A solution of compound 2 (5.00 g, 22.81 mmol) in anhydrous THF (10 mL) was added to a suspension of NaH (60% in mineral oil, 1.09 g, 27.37 mmol), and the resulting suspension was stirred for 1 h. Iodomethane (2.84 mL, 45.61 mmol) was added dropwise to the reaction mixture, which was stirred for an additional 45 min. After cooling to 0 °C in an ice bath, the reaction mixture was quenched slowly with H₂O and extracted with DCM. The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄, and concentrated under a vacuum to give a yellow oil, which was purified by column chromatography on silica gel with ethyl acetate/petroleum ether (1:3) as eluents to provide compound 7 as a light yellow oil (5.28 g, 99% yield). ¹H NMR (400 MHz, CDCl₃): δ 3.69–3.64 (m, 12H), 3.57–3.55 (m, 2H), 3.40 (t, *J* = 5.2 Hz, 2H), 3.38 (s, 3H).

19-Azido-2,5,8,11,14,17-hexaoxanonadecane (8).^{11b} Compound 8 was obtained from compound 3 as a light yellow oil in 87% yield by employing the same synthetic procedures as compound 7. (Compound 8 was purified by silica gel column chromatography (ethyl acetate/petroleum ether = 1:2) as a light yellow oil in 87% yield (1.36 g) by employing the same synthetic procedures as compound 7.) ¹H NMR (400 MHz, CDCl₃): δ 3.69–3.63 (m, 20H), 3.56–3.54 (m, 2H), 3.40 (t, J = 5.1 Hz, 2H), 3.38 (s, 3H).

25-Azido-2,5,8,11,14,17,20,23-octaoxapentacosane (9).^{11c} Compound 9 was obtained from compound 4 as a light yellow oil in 94% yield by employing the same synthetic procedures as compound 7. (Compound 9 was purified by silica gel column chromatography (ethyl acetate/petroleum ether = 1:2) as a light yellow oil in 94% yield (1.93 g) by employing the same synthetic procedures as compound 7.) ¹H NMR (400 MHz, CDCl₃): δ 3.69–3.63 (m, 28H), 3.56–3.54 (m, 2H), 3.40 (t, J = 5.1 Hz, 2H), 3.38 (s, 3H).

Preparation of M-OEG Monoazides 10 and 11. 14-Azido-1,1,1-trifluoro-2,2-bis(trifluoromethyl)-3,6,9,12-tetraoxatetradecane (10).^{11d} To a solution of alcohol 5 (5.0 g, 12.1 mmol) in THF (25 mL) was added a solution of NaOH (1.70 g, 42.5 mmol) in water (6.8 mL). After the solution was cooled to 0 $^{\circ}$ C, a solution of ptoluenesulfonyl chloride (2.77 g, 14.6 mmol) in THF (15 mL) was slowly added, and the resulting mixture was stirred overnight at rt. The reaction mixture was concentrated under a vacuum. The residue was dissolved in water (30 mL) and extracted with DCM. The organic layers were concentrated under a vacuum to obtain crude sulfonate as a light yellow oil. To a solution of crude sulfonate in DMF (27 mL) was added NaN₃ (1.18 g, 18.2 mmol), and the resulting mixture was stirred at 80 °C for 4 h. Then, the reaction mixture containing excess NaN₃ was filtered through a pad of Celite, concentrated under a vacuum, dissolved in water (50 mL), and extracted with DCM. The combined organic layers were dried over anhydrous Na₂SO₄, concentrated under a vacuum, and purified by flash chromatography on silica gel with ethyl acetate/petroleum ether (1:9) as eluents to obtain azide 10 as a light yellow oil (4.2 g, 70% yield). ¹H NMR (400 MHz, CDCl₃): δ 4.16 (t, J = 4.9 Hz, 2H), 3.74 (t, J = 4.8 Hz, 2H), 3.70-3.65 (m, 10H), 3.39 (t, J = 5.0 Hz, 2H). ¹⁹F NMR (376 MHz, $CDCl_3$): δ -73.55.

26-Azido-1, 1, 1-trifluoro-2, 2-bis(trifluoromethyl)-3, 6, 9, 12, 15, 18, 21, 24-octaoxahexacosane (11).^{11e} Compound 11 was obtained from compound 6 as a light yellow oil in 71% yield by employing the same synthetic procedures as compound 10. (Compound 11 was purified by silica gel column chromatography (ethyl acetate/ petroleum ether = 1:2) as a light yellow oil in 71% yield (3.70 g) by employing the same synthetic procedures as compound 10.) ¹H NMR (400 MHz, CDCl₃): δ 4.15 (t, J = 4.9 Hz, 2H), 3.73 (t, J = 4.9 Hz, 2H), 3.69–3.63 (m, 26H), 3.39 (t, J = 5.1 Hz, 2H). ¹⁹F NMR (376 MHz, CDCl₃): δ –73.57.

Synthesis of aza-M-OEGs 12–19. 3,6,9,12,15,18,21,27,30,33,-36,39,42,45-Tetradecaoxa-24-azaheptatetracontane-1,47-diol (12). Under an atmosphere of H₂, a mixture of compound 4 (200.0

Note

mg, 0.51 mmol) and Pd/C (10% on carbon, 107.6 mg, 0.10 mmol) in dry MeOH (10 mL) was stirred at rt overnight. The mixture was filtrated through a pad of Celite, and the filtrate was concentrated. The crude product was purified by column chromatography on silica gel to give **12** as a light yellow oil (130 mg, 71% yield) with MeOH/ DCM (1:10) as eluents. ¹H NMR (400 MHz, CDCl₃): δ 3.74–3.71 (m, 4H), 3.67–3.60 (m, 56H), 2.89 (t, *J* = 5.3 Hz, 4H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 72.8, 72.7, 70.61, 70.56, 70.53, 70.50, 70.47, 70.4, 70.33, 70.26, 70.2, 68.0, 61.5, 48.3. HRMS (ESI) *m/z*: [M + Na]⁺ calcd for C₃₂H₆₇NNaO₁₆⁺, 744.4352; found, 744.4346.

3,6,9,15,18,21-Hexaoxa-12-azatricosane-1,23-diol (13). Compound 13 was obtained from compound 2 as a light yellow oil in 71% yield by employing the same synthetic procedures as compound 12. (Compound 13 was purified by silica gel column chromatography (MeOH/DCM = 1:10) as a light yellow oil in 71% yield (120 mg) by employing the same synthetic procedures as compound 12.) ¹H NMR (400 MHz, CDCl₃): δ 3.73–3.71 (m, 4H), 3.67–3.59 (m, 24H), 2.84 (t, *J* = 5.1 Hz, 4H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 72.8, 72.7, 70.45, 70.35, 70.03, 70.01, 69.8, 61.3, 48.8. HRMS (ESI) *m/z*: [M + Na]⁺ calcd for C₁₆H₃₅NNaO₈⁺, 392.2255; found, 392.2252.

3,6,9,12,15,21,24,27,30,33-Decaoxa-18-azapentatriac ontane-1,35-diol (14). Compound 14 was obtained from compound 3 as a light yellow oil in 80% yield by employing the same synthetic procedures as compound 12. (Compound 14 was purified by silica gel column chromatography (MeOH/DCM = 1:10) as a light yellow oil in 80% yield (142 mg) by employing the same synthetic procedures as compound 12.) ¹H NMR (400 MHz, CDCl₃): δ 3.66–3.64 (m, 5H), 3.62–3.57 (m, 31H), 3.51 (dt, *J* = 17.6, 5.1 Hz, 8H), 2.82 (t, *J* = 5.1 Hz, 4H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 72.7, 70.60, 70.56, 70.53, 70.51, 70.47, 70.44, 70.42, 70.3, 70.2, 68.6, 61.5, 48.4. HRMS (ESI) *m/z*: [M + Na]⁺ calcd for C₂₄H₅₁NNaO₁₂⁺, 568.3303; found, 568.3304.

Di(2,5,8,11-tetraoxatridecan-13-yl)amine (15). Compound 15 was obtained from compound 7 as a light yellow oil in 73% yield by employing the same synthetic procedures as compound 12. (Compound 15 was purified by silica gel column chromatography (MeOH/DCM = 1:30) as a light yellow oil in 73% yield (124 mg) by employing the same synthetic procedures as compound 12.) ¹H NMR (400 MHz, CDCl₃): δ 3.66–3.59 (m, 24H), 3.56 (dd, J = 5.8, 3.5 Hz, 4H), 3.38 (s, 6H), 2.84 (t, J = 5.3 Hz, 4H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 71.9, 70.53, 70.51, 70.47, 70.4, 70.32, 70.27, 59.0, 49.1. HRMS (ESI) m/z, $[M + Na]^+$ calcd for $C_{18}H_{39}NNaO_8^+$: 420.2568; found, 420.2563.

Di(2,5,8,11,14,17-hexaoxanonadecan-19-yl)amine (16). Compound 16 was obtained from compound 8 as a light yellow oil in 85% yield by employing the same synthetic procedures as compound 12. (Compound 16 was purified by silica gel column chromatography (MeOH/DCM = 1:30) as a light yellow oil in 85% yield (152 mg) by employing the same synthetic procedures as compound 12.) ¹H NMR (400 MHz, CDCl₃): δ 3.59–3.57 (m, 40H), 3.49–3.47 (m, 4H), 3.31 (s, 6H), 2.84 (t, *J* = 5.2 Hz, 4H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 71.9, 70.6, 70.52, 70.50, 70.48, 70.45, 70.41, 70.2, 69.7, 59.0, 48.8. HRMS (ESI) *m*/*z*: [M + Na]⁺ calcd for C₂₆H₅₅NNaO₁₂⁺, 596.3616; found, 596.3615.

Di(2,5,8,11,14,17,20,23-octaoxapentacosan-25-yl)amine (17). Compound 17 was obtained from compound 9 as a light yellow oil in 69% yield by employing the same synthetic procedures as compound 12. (Compound 17 was purified by silica gel column chromatography (MeOH/DCM = 1:20) as a light yellow oil in 69% yield (126 mg) by employing the same synthetic procedures as compound 12.) ¹H NMR (400 MHz, CDCl₃): δ 3.59–3.53 (m, 56H), 3.51–3.48 (m, 4H), 3.31 (d, J = 5.3 Hz, 6H), 2.79 (t, J = 5.2 Hz, 4H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 71.7, 70.4, 70.3, 70.11, 70.07, 58.8, 48.9. HRMS (ESI) m/z, [M + Na]⁺ calcd for C₃₄H₇₁NNaO₁₆⁺: 772.4665; found, 772.4661.

Bis (14, 14, 14-trifluoro-13, 13-bis(trifluoromethyl)-3, 6, 9, 12-tetraoxatetradecyl)amine (18). Compound 18 was obtained from compound 10 as a light yellow oil in 71% yield by employing the same synthetic procedures as compound 12. (Compound 18 was purified by silica gel column chromatography (MeOH/DCM = 1:40) as a

light yellow oil in 71% yield (130 mg) by employing the same synthetic procedures as compound **12**.) ¹H NMR (400 MHz, CDCl₃): δ 4.16 (t, *J* = 4.9 Hz, 4H), 3.73 (t, *J* = 4.8 Hz, 4H), 3.69–3.61 (m, 20H), 2.86 (t, *J* = 5.3 Hz, 4H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 120.4 (q, *J* = 293.1 Hz), 79.8 (dd, *J* = 59.6, 29.8 Hz), 71.1, 70.6, 70.4, 70.3, 69.4, 69.3, 49.1. ¹⁹F NMR (376 MHz, CDCl₃): δ –73.57. HRMS (ESI) *m/z*: [M + Na]⁺ calcd for C₂₄H₃₃F₁₈NNaO₈⁺, 828.1811; found, 828.1812.

For the scaled synthesis of 18, under an atmosphere of H_2 , a mixture of compound 10 (1.0 g, 2.3 mmol) and Pd/C (10% on carbon, 487 mg, 0.46 mmol) in dry MeOH (46 mL) was stirred at rt overnight. The mixture was filtrated through a pad of Celite, and the filtrate was concentrated. The crude product was purified by column chromatography on silica gel to give 12 as a light yellow oil (570 mg, 62% yield) with MeOH/DCM (1:40) as eluents.

Bis(26,26,26-trifluoro-25,25-bis(trifluoromethyl)-3,6,9,12,-15,18,21,24-octaoxahexacosyl)amine (**19**). Compound **19** was obtained from compound **11** as a light yellow oil in 79% yield by employing the same synthetic procedures as compound **12**. (Compound **19** was purified by silica gel column chromatography (MeOH/DCM = 1:30) as a light yellow oil in 79% yield (149 mg) by employing the same synthetic procedures as compound **12**.) ¹H NMR (400 MHz, CDCl₃): δ 4.16 (t, *J* = 4.9 Hz, 4H), 3.74 (t, *J* = 4.8 Hz, 4H), 3.68–3.59 (m, 52H), 2.84 (t, *J* = 5.3 Hz, 4H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 120.3 (q, *J* = 293.3 Hz), 79.7 (dd, *J* = 59.6, 29.6 Hz), 71.0, 70.61, 70.57, 70.53, 70.49, 70.4, 70.3, 69.4, 69.3, 49.1. ¹⁹F NMR (376 MHz, CDCl₃): δ -73.55. HRMS (ESI) *m/z*: [M + Na]⁺ calcd for C₄₀H₆₅F₁₈NNaO₁₆⁺, 1180.3908; found, 1180.3909.

Scaled Synthesis of **19**. Under an atmosphere of H_2 , a mixture of compound **11** (1.6 g, 2.6 mmol) and Pd/C (10% on carbon, 555 mg, 0.52 mmol) in dry MeOH (52 mL) was stirred at rt overnight. The mixture was filtrated through a pad of Celite, and the filtrate was concentrated. The crude product was purified by column chromatography on silica gel to give **12** as a light yellow oil (985 mg, 66% yield) with MeOH/DCM (1:30) as eluents.

Preparation of Functionalized and Multiarm M-OEGs 20-33. N,N-Di(2,5,8,11-tetraoxatridecan-13-yl)benzamide (20). Under an atmosphere of H₂, a mixture of compound 7 (200.0 mg, 0.86 mmol) and Pd/C (10% on carbon, 182.5 mg, 0.17 mmol) in dry MeOH (17 mL) was stirred at rt overnight. The mixture was filtrated through a pad of Celite, and the filtrate was concentrated. Under argon atmosphere, the crude product was stirred in dry DCM. After the mixture was cooled to 0 °C in an ice bath, Et₃N (0.25 mL, 1.81 mmol) and benzoyl chloride (0.12 mL, 1.03 mmol) were added, and the mixture was stirred for 1 h at 0 °C and another 2 h at rt. The reaction mixture was poured into water and extracted with DCM. The combined organic layers were washed with saturated NH4Cl, dried over anhydrous Na2SO4, and then filtered and concentrated in a vacuum. The crude product was purified by column chromatography on silica gel to give 20 a light yellow oil (120 mg, 56% yield) with MeOH/DCM (1:40) as eluents. ¹H NMR (400 MHz, CDCl₃): δ 7.43-7.36 (m, 5H), 3.76 (s, 4H), 3.66-3.58 (m, 20H), 3.55-3.50 (m, 8H), 3.37 (s, 6H). ${}^{13}C{}^{1}H$ NMR (101 MHz, CDCl₃): δ 172.3, 136.8, 129.2, 128.3, 126.9, 71.9, 70.59, 70.55, 70.5, 69.1, 59.0, 49.6, 45.3. HRMS (ESI) m/z: $[M + Na]^+$ calcd for $C_{25}H_{43}NNaO_9^+$, 524.2830; found, 524.2828.

N,N-Di(2,5,8,11,14,17-hexaoxanonadecan-19-yl) benzamide (21). Compound 21 was obtained from compound 8 as a light yellow oil in 61% yield by employing the same synthetic procedures as compound 20. (Compound 21 was purified by silica gel column chromatography (MeOH/DCM = 1:40) as a light yellow oil in 61% yield (128 mg) by employing the same synthetic procedures as compound 20.) ¹H NMR (400 MHz, CDCl₃): δ 7.35–7.29 (m, 5H), 3.69 (s, 3H), 3.60–3.53 (m, 35H), 3.48–3.45 (m, 10H), 3.30 (s, 6H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 172.2, 136.7, 129.1, 128.2, 126.8, 71.8, 70.5, 70.45, 70.38, 69.0, 58.9, 49.5, 45.2. HRMS (ESI) *m*/*z*: [M + Na]⁺ calcd for C₃₃H₅₉NNaO₁₃⁺, 700.3879; found, 700.3872.

N,N-Di(2,5,8,11,14,17,20,23-octaoxapentacosan-25-yl)benzamide (22). Compound 22 was obtained from compound 9 as a light yellow oil in 52% yield by employing the same synthetic procedures as compound **20**. (Compound **22** was purified by silica gel column chromatography (MeOH/DCM = 1:40) as a light yellow oil in 52% yield (108 mg) by employing the same synthetic procedures as compound **20**.) ¹H NMR (400 MHz, CDCl₃): δ 7.42–7.37 (m, SH), 3.76 (s, 4H), 3.66–3.59 (m, 50H), 3.56–3.52 (m, 10H), 3.38 (s, 6H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 172.3, 136.7, 129.2, 128.3, 126.8, 71.8, 70.5, 70.4, 69.0, 59.0, 49.6, 45.2. HRMS (ESI) *m/z*: [M + Na]⁺ calcd for C₄₁H₇₅NNaO₁₇⁺, 876.4927; found, 876.4919.

15-Oxo-14-(2,5,8,11-tetraoxatridecan-13-yl)-2,5,8,11-tetraoxa-14-azaoctadecan-18-oic Acid (23). Under an atmosphere of H₂, a mixture of compound 7 (200.0 mg, 0.86 mmol) and Pd/C (10% on carbon, 182.5 mg, 0.17 mmol) in dry MeOH (17 mL) was stirred at rt overnight. The mixture was filtrated through a pad of Celite, and the filtrate was concentrated. Under an argon atmosphere, a solution of the crude product and phthalic anhydride (85.8 mg, 0.86 mmol) in 10 mL of dry THF was refluxed in an oil bath for 3 h. The solvent was evaporated under reduced pressure, and the residue was dissolved in DCM. The solution was washed with saturated NH₄Cl, dried over anhydrous Na₂SO₄, and then filtered and concentrated in a vacuum. After removal of the solvent, the crude product was purified by column chromatography on silica gel to give 23 a light yellow oil (106 mg, 50% yield) with MeOH/DCM (1:20) as eluents. ¹H NMR (400 MHz, CDCl₃): δ 3.65–3.54 (m, 32H), 3.38 (s, 6H), 2.77 (t, J = 6.5Hz, 2H), 2.65 (t, J = 6.5 Hz, 2H). ¹³C{¹H} NMR (101 MHz, CDCl₃): *δ* 175.6, 173.0, 71.9, 70.8, 70.6, 70.54, 70.47, 70.42, 70.37, 70.3, 69.4, 67.0, 59.0, 58.9 49.0, 46.4, 29.9, 28.1. HRMS (ESI) m/z: $[M + Na]^+$ calcd for $C_{22}H_{43}NNaO_{11}^+$, 520.2728; found, 520.2728.

20-(2,5,8,11,14,17-Hexaoxanonadecan-19-yl)-21-oxo-2,5,8,11,14,17-hexaoxa-20-azatetracosan-24-oic Acid (24). Compound 24 was obtained from compound 8 as a light yellow oil in 50% yield by employing the same synthetic procedures as compound 23. (Compound 24 was purified by silica gel column chromatography (MeOH/DCM = 1:30) as a light yellow oil in 50% yield (105 mg) by employing the same synthetic procedures as compound 23.) ¹H NMR (400 MHz, CDCl₃): δ 3.59–3.53 (m, 42H), 3.51–3.48 (m, 6H), 3.31 (s, 6H), 2.69 (t, J = 6.6 Hz, 2H), 2.58 (t, J = 6.6 Hz, 2H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 175.3, 172.8, 71.8, 70.7, 70.5, 70.44, 70.41, 70.38, 70.32, 70.28, 70.2, 69.3, 68.9, 58.9, 48.9, 46.3, 29.8, 28.1. HRMS (ESI) m/z: [M + Na]⁺ calcd for C₃₀H₅₉NNaO₁₅⁺, 696.3777; found, 696.3773.

27-Oxo-26-(2,5,8,11,14,17,20,23-octaoxapentacosan-25-yl)-2,5,8,11,14,17,20,23-octaoxa-26-azatriacontan-30-oic Acid (25). Compound 25 was obtained from compound 9 as a light yellow oil in 54% yield by employing the same synthetic procedures as compound 23. (Compound 25 was purified by silica gel column chromatography (MeOH/DCM = 1:20) as a light yellow oil in 54% yield (112 mg) by employing the same synthetic procedures as compound 23.) ¹H NMR (400 MHz, CDCl₃): δ 3.68–3.58 (m, 58H), 3.57–3.54 (m, 6H), 3.38 (s, 6H), 2.78 (t, *J* = 6.6 Hz, 2H), 2.65 (t, *J* = 6.6 Hz, 2H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 174.9, 173.3, 72.0, 70.9, 70.7, 70.63, 70.60, 70.57, 70.5, 70.4, 69.4, 69.0, 59.1, 49.1, 46.5, 30.2, 28.3. HRMS (ESI) *m/z*: [M + Na]⁺ calcd for C₃₈H₇₅NNaO₁₉⁺, 872.4825; found, 872.4824.

Benzyl Bis(2-(2-(2-(2-hydroxyethoxy)ethoxy) ethoxy)ethyl)carbamate (26). Under an atmosphere of H_2 , the mixture of compound 2 (200.0 mg, 0.86 mmol) and Pd/C (10% on carbon, 182.5 mg, 0.17 mmol) in dry MeOH (17 mL) was stirred at rt overnight. The mixture was filtrated through a pad of Celite, and the filtrate was concentrated. Under an argon atmosphere, the crude product was stirred in dry DCM, and Et₃N (0.15 mL, 1.03 mmol) and CbzCl (0.12 mL, 0.86 mmol) were added in the mixture at 0 °C; the mixture was stirred for 3 h. The reaction mixture was poured into water and extracted with DCM. The combined organic layers were dried over anhydrous Na₂SO₄ and then filtered and concentrated in a vacuum. The crude product was purified by column chromatography on silica gel to give 26 as a clear oil (111 mg, 48% yield) with MeOH/ DCM (1:30) as eluents. ¹H NMR (400 MHz, CDCl₃): δ 7.36–7.31 (m, 5H), 5.12 (s, 2H), 3.72 (t, J = 4.5 Hz, 4H), 3.65-3.53 (m, 28H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 156.2, 136.8, 128.6, 128.04, 127.95, 72.7, 70.7, 70.6, 70.5, 70.4, 69.8, 69.5, 67.2, 61.7, 48.3, 47.7.

pubs.acs.org/joc

HRMS (ESI) m/z: $[M + Na]^+$ calcd for $C_{24}H_{41}NNaO_{10}^+$, 526.2623; found, 526.2618.

Benzyl Bis(17-hydroxy-3,6,9,12,15-pentaoxahepta decyl)carbamate (27). Compound 27 was obtained from compound 3 as a light yellow oil in 56% yield by employing the same synthetic procedures as compound 26. (Compound 27 was purified by silica gel column chromatography (MeOH/DCM = 1:30) as a light yellow oil in 56% yield (123 mg) by employing the same synthetic procedures as compound 26.) ¹H NMR (400 MHz, CDCl₃): δ 7.38–7.31 (m, 5H), 5.12 (s, 2H), 3.72 (t, *J* = 4.5 Hz, 4H), 3.66–3.51 (m, 44H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 156.2, 136.8, 128.5, 128.0, 127.9, 72.7, 70.6, 70.50, 70.48, 70.45, 70.38, 70.3, 70.2, 69.7, 69.4, 67.1, 61.6, 48.1, 47.6. HRMS (ESI) *m*/*z*: [M + Na]⁺ calcd for C₃₂H₅₇NNaO₁₄⁺, 702.3671; found, 702.3668.

Benzyl Bis(23-hydroxy-3,6,9,12,15,18,21-heptaoxa tricosyl)carbamate (28). Compound 28 was obtained from compound 4 as a light yellow oil in 52% yield by employing the same synthetic procedures as compound 26. (Compound 28 was purified by silica gel column chromatography (MeOH/DCM = 1:30) as a light yellow oil in 52% yield (112 mg) by employing the same synthetic procedures as compound 26.) ¹H NMR (400 MHz, CDCl₃): δ 7.38–7.29 (m, SH), 5.12 (s, 2H), 3.72 (t, *J* = 4.5 Hz, 4H), 3.66–3.51 (m, 60H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 156.0, 136.6, 128.4, 127.8, 127.7, 72.6, 70.39, 70.36, 70.32, 70.29, 70.2, 70.0, 69.5, 69.2, 66.9, 61.4, 48.0, 47.5. HRMS (ESI) *m/z*: [M + Na]⁺ calcd for C₄₀H₇₃NNaO₁₈⁺, 878.4720; found, 878.4713.

Benzyl Di(2,5,8,11-tetraoxatridecan-13-yl) carbamate (29). Compound 29 was obtained from compound 7 as a light yellow oil in 50% yield by employing the same synthetic procedures as compound 26. (Compound 29 was purified by silica gel column chromatography (MeOH/DCM = 1:40) as a light yellow oil in 50% yield (109 mg) by employing the same synthetic procedures as compound 26.) ¹H NMR (400 MHz, CDCl₃): δ 7.35–7.30 (m, 5H), 5.12 (s, 2H), 3.65–3.51 (m, 32H), 3.37 (s, 6H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 156.2, 136.8, 128.5, 128.0, 127.9, 72.0, 70.65, 70.60, 70.56, 70.5, 70.4, 69.7, 69.5, 67.1, 59.1, 48.2, 47.7. HRMS (ESI) m/z: [M + Na]⁺ calcd for C₂₆H₄₅NNaO₁₀⁺, 554.2936; found, 554.2938.

Benzyl Di(2,5,8,11,14,17-hexaoxanonadecan-19-yl)carbamate (**30**). Compound **30** was obtained from compound **8** as a light yellow oil in 56% yield by employing the same synthetic procedures as compound **26**. (Compound **30** was purified by silica gel column chromatography (MeOH/DCM = 1:40) as a light yellow oil in 56% yield (124 mg) by employing the same synthetic procedures as compound **26**.) ¹H NMR (400 MHz, CDCl₃): δ 7.38–7.31 (m, 5H), 5.12 (s, 2H), 3.67–3.63 (m, 36H), 3.58–3.52 (m, 12H), 3.38 (s, 6H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 156.4, 136.7, 128.6, 128.1, 127.9, 72.0, 70.63, 70.59, 70.57, 70.5, 70.4, 69.8, 69.6, 67.3, 59.1, 48.2, 47.6. HRMS (ESI) *m/z*: [M + Na]⁺ calcd for C₃₄H₆₁NNaO₁₄⁺, 730.3984; found, 730.3981.

Benzyl Di(2,5,8,11,14,17,20,23-octaoxapentacosan-25-yl)carbamate (**31**). Compound **31** was obtained from compound **9** as a light yellow oil in 51% yield by employing the same synthetic procedures as compound **26**. (Compound **31** was purified by silica gel column chromatography (MeOH/DCM = 1:30) as a light yellow oil in 51% yield (110 mg) by employing the same synthetic procedures as compound **26**.) ¹H NMR (400 MHz, CDCl₃): δ 7.38–7.30 (m, 5H), 5.12 (s, 2H), 3.68–3.51 (m, 64H), 3.38 (s, 6H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 156.1, 136.7, 128.4, 127.9, 127.8, 71.8, 70.5, 70.45, 70.39, 70.2, 69.6, 69.3, 67.0, 58.9, 48.0, 47.5. HRMS (ESI) *m/z*: [M + Na]⁺ calcd for C₄₂H₇₇NNaO₁₈⁺, 906.5033; found, 906.5031.

 N^1, N^1 -Bis(2-(4-(2-methoxy)butoxy)ethoxy)- N^3, N^3, N^5, N^5 tetra(2,5,8,11-tetraoxatridecan-13-yl) benzene-1,3,5-tricarboxamide (**32**). To a solution of compound 7 (167 mg, 0.50 mmol) in dry DCM (15 mL) at 0 °C were added 1,3,5-benzenetricarbonyl trichloride (33.4 mg, 0.13 mmol) and Et₃N (0.05 mL, 0.38 mmol), and the reaction was stirred for 3 h under an Ar atmosphere. The reaction mixture was poured into water and extracted with DCM. The organic layers were washed with saturated NH₄Cl, dried over Na₂SO₄, and concentrated in a vacuum. The product was isolated by column chromatography on silica gel to give **32** as a light yellow oil (127 mg, 95% yield) with MeOH/DCM (1:20) as eluents. ¹H NMR (400 MHz, CDCl₃): δ 7.42 (s, 3H), 3.69–3.67 (m, 12H), 3.59–3.44 (m, 84H), 3.31 (s, 18H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 170.4, 137.0, 126.2, 71.7, 70.39, 70.36, 70.3, 70.1, 68.9, 68.8, 58.8, 49.6, 45.1. HRMS (ESI) *m/z*: [M + Na]⁺ calcd for C₆₃H₁₁₇N₃NaO₂₇⁺, 1370.7767; found, 1370.7767

 N^1 , N^1 -Bis((2,5,8,13,16-pentaoxaoctadecan-18-yl)oxy)-N³, N^3 , N^5 , N^5 -tetra(2,5,8,11,14,17-hexaoxanonadecan-19-yl)benzene-1,3,5-tricarboxamide (**33**). Compound **33** was obtained from compound **8** as a light yellow oil in 90% yield by employing the same synthetic procedures as compound **32**. (Compound **33** was purified by silica gel column chromatography (MeOH/DCM = 1:20) as a light yellow oil in 90% yield (221 mg) by employing the same synthetic procedures as compound **32**.) ¹H NMR (400 MHz, CDCl₃): δ 7.41 (s, 3H), 3.69–3.64 (m, 12H), 3.59–3.55 (m, 98H), 3.52–3.47 (m, 19H), 3.45–3.44 (m, 15H), 3.31 (s, 18H). ¹³C{¹H} ¹H NMR (400 MHz, CDCl₃): δ 7.41 (s, 3H), 3.69–3.64 (m, 12H), 3.59–3.55 (m, 98H), 3.52–3.47 (m, 19H), 3.45–3.44 (m, 15H), 3.31 (s, 18H). ¹³C NMR (101 MHz, CDCl₃): δ 169.9, 136.5, 125.7, 71.29, 71.26, 69.9, 69.85, 69.81, 68.5, 68.2, 58.34, 58.30, 49.1, 44.6. HRMS (ESI) m/z: [M + Na]⁺ calcd for C₈₇H₁₆₅N₃NaO₃₉⁺, 1899.0912; found, 1899.0909.

Preparation of ¹⁹F MRI-Traceable Biomaterials and Their Building Blocks 34-41. 1,1,1-Trifluoro-16-oxo-15-(14,14,14-trifluoro-13,13-bis (trifluoromethyl)-3,6,9,12-tetraoxatetradecyl)-2,2bis (trifluoromethyl)-3,6,9,12-tetraoxa-15-azanonadecan-19-oic Acid (34). Compound 34 was obtained from compound 12 as a light yellow oil in 58% yield by employing the same synthetic procedures as compound 23. (Compound 34 was purified by silica gel column chromatography (MeOH/DCM = 1:40) as a light yellow oil in 58% yield (120 mg) by employing the same synthetic procedures as compound 23.) ¹H NMR (400 MHz, CDCl₃): δ 4.16 (t, J = 4.8 Hz, 4H), 3.73 (t, J = 4.8 Hz, 4H), 3.68-3.56 (m, 24H), 2.79 (t, J = 6.6Hz, 2H), 2.65 (t, J = 6.6 Hz, 2H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 176.3, 173.1, 120.4 (q, *J* = 293.7, 292.8 Hz), 79.8 (dd, *J* = 60.6, 30.3 Hz), 71.17, 71.15, 70.9, 70.71, 70.66, 70.64, 70.59, 70.4, 69.48, 69.46, 69.43, 69.37, 69.0, 49.1, 46.6, 30.0, 28.2. ¹⁹F NMR (376 MHz, CDCl₃): δ -73.54. HRMS (ESI) m/z: [M + Na]⁺ calcd for C₂₈H₃₇F₁₈NNaO₁₁⁺, 928.1971; found, 928.1970.

1,1,1-Trifluoro-28-oxo-27-(26,26,26-trifluoro-25,25-bis-(trifluoromethyl)-3,6,9,12,15,18,21,24-octaoxahexa cosyl)-2,2-bis-(trifluoromethyl)-3,6,9,12,15,18,21,24-octaoxa-27-azahentriacontan-31-oic Acid (35). Compound 35 was obtained from compound 13 as a light yellow oil in 71% yield by employing the same synthetic procedures as compound 23. (Compound 35 was purified by silica gel column chromatography (MeOH/DCM = 1:30) as a light yellow oil in 71% yield (145 mg) by employing the same synthetic procedures as compound 23.) ¹H NMR (400 MHz, CDCl₃): δ 4.16 (t, J = 4.9 Hz, 4H), 3.73 (t, J = 4.9 Hz, 4H), 3.69-3.57 (m, 56H), 2.79 (t, J = 6.5 Hz, 2H), 2.65 (t, J = 6.5 Hz, 2H). ¹³C{¹H} NMR (101 MHz, $CDCl_3$): δ 175.2, 173.1, 120.3 (q, J = 293.0 Hz), 79.8 (dd, J = 62.1, 30.3 Hz), 71.1, 70.8, 70.62, 70.58, 70.54, 70.51, 70.49, 70.4, 69.4, 69.3, 69.0, 49.0, 46.5, 30.0, 28.2. ¹⁹F NMR (376 MHz, CDCl₃): δ -73.55. HRMS (ESI) m/z: $[M + Na]^+$ calcd for $C_{44}H_{69}F_{18}NNaO_{19}^+$, 1280.4069; found, 1280.4066.

N,N-Bis(14,14,14-trifluoro-13,13-bis(trifluoromethyl)-3,6,9,12tetraoxatetradecyl)benzamide (**36**). Compound **36** was obtained from compound **12** as a light yellow oil in 59% yield by employing the same synthetic procedures as compound **20**. (Compound **36** was purified by silica gel column chromatography (MeOH/DCM = 1:60) as a light yellow oil in 59% yield (126 mg) by employing the same synthetic procedures as compound **20**.) ¹H NMR (400 MHz, CDCl₃): δ 7.42–7.36 (m, 5H), 4.15 (t, *J* = 4.8 Hz, 4H), 3.77–3.50 (m, 28H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 172.4, 136.9, 129.3, 128.4, 126.9, 120.4 (q, *J* = 293.8 Hz), 79.9 (dd, *J* = 60.6, 30.3 Hz), 71.2, 70.70, 70.68, 70.5, 69.5, 69.4, 69.2, 49.7, 45.4. ¹⁹F NMR (376 MHz, CDCl₃): δ –73.47. HRMS (ESI) *m/z*: [M + Na]⁺ calcd for C₃₁H₃₇F₁₈NNaO₉⁺, 932.2073; found, 932.2073.

N,N-Bis(26,26,26-trifluoro-25,25-bis(trifluoro methyl)-3,6,9,12,15,18,21,24-octaoxahexacosyl) benzamide (**37**). Compound 37 was obtained from compound **13** as a light yellow oil in

63% yield by employing the same synthetic procedures as compound **20**. (Compound **37** was purified by silica gel column chromatography (MeOH/DCM = 1:60) as a light yellow oil in 63% yield (130 mg) by employing the same synthetic procedures as compound **20**.) ¹H NMR (400 MHz, CDCl₃): δ 7.42–7.37 (m, 5H), 4.15 (t, *J* = 4.9 Hz, 4H), 3.76–3.72 (m, 10H), 3.69–3.58 (m, 45H), 3.55–3.50 (m, 5H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 156.0, 136.7, 128.4, 127.9, 127.8, 120.2 (q, *J* = 292.9 Hz), 79.7 (dd, *J* = 60.6, 30.3 Hz), 71.0, 70.54, 70.51, 70.47, 70.4, 70.2, 69.6, 69.3, 69.2, 66.9, 48.0, 47.6; ¹⁹F NMR (376 MHz, CDCl₃): δ –73.53. HRMS (ESI) *m/z*: [M + Na]⁺ calcd for C₄₇H₆₉F₁₈NNaO₁₇⁺, 1284.4170; found, 1284.4169.

Benzyl Bis(14,14,14-trifluoro-13,13-bis(trifluoro methyl)-3,6,9,12tetraoxatetradecyl)carbamate (**38**). Compound **38** was obtained from compound **12** as a light yellow oil in 62% yield by employing the same synthetic procedures as compound **26**. (Compound **38** was purified by silica gel column chromatography (MeOH/DCM = 1:60) as a light yellow oil in 62% yield (133 mg) by employing the same synthetic procedures as compound **26**.) ¹H NMR (400 MHz, CDCl₃): δ 7.35–7.30 (m, SH), 5.13 (s, 2H), 4.15 (t, *J* = 4.9 Hz, 4H), 3.72 (t, *J* = 4.9 Hz, 4H), 3.67–3.52 (m, 24H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 156.2, 136.9, 128.5, 128.0, 127.9, 120.4 (q, *J* = 292.9 Hz), 79.8 (dd, *J* = 59.6, 30.3 Hz), 71.1, 70.7, 70.5, 70.4, 69.8, 69.5, 69.3, 67.1, 48.2, 47.7. ¹⁹F NMR (376 MHz, CDCl₃): δ –73.57. HRMS (ESI) *m*/*z*: [M + Na]⁺ calcd for C₃₂H₃₉F₁₈NNaO₁₀⁺, 962.2179; found, 962.2176.

Benzyl Bis(26,26,26-trifluoro-25,25-bis(trifluoro methyl)-3,6,9,12,15,18,21,24-octaoxahexacosyl)carbamate (**39**). Compound **39** was obtained from compound **13** as a light yellow oil in 67% yield by employing the same synthetic procedures as compound **26**. (Compound **39** was purified by silica gel column chromatography (MeOH/DCM = 1:60) as a light yellow oil in 67% yield (140 mg) by employing the same synthetic procedures as compound **26**.) ¹H NMR (400 MHz, CDCl₃): δ 7.38–7.30 (m, 5H), 5.12 (s, 2H), 4.15 (t, *J* = 4.9 Hz, 4H), 3.73 (t, *J* = 4.9 Hz, 5H), 3.69–3.61 (m, 46H), 3.58–3.51 (m, 9H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 172.2, 136.8, 129.1, 128.3, 126.8, 120.3 (q, *J* = 291.9 Hz), 79.7 (dd, *J* = 59.3, 28.3 Hz), 71.02, 70.97, 70.6, 70.51, 70.48, 69.3, 69.2, 69.0, 49.6, 45.2. ¹⁹F NMR (376 MHz, CDCl₃): δ –73.55. HRMS (ESI) *m/z*: [M + Na]⁺ calcd for C₄₈H₇₁F₁₈NNaO₁₈⁺, 1314.4276; found, 1314.4274.

Compound **40** was obtained from compound **18** as a light yellow oil in 93% yield by employing the same synthetic procedures as compound **32**. (Compound **40** was purified by silica gel column chromatography (MeOH/DCM = 1:30) as a light yellow oil in 93% yield (148 mg) by employing the same synthetic procedures as compound **32**.) ¹H NMR (400 MHz, CDCl₃): δ 7.50 (s, 3H), 4.15 (t, J = 4.8 Hz, 12H), 3.76–3.58 (m, 68H), 3.52–3.51 (m, 16H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 170.7, 137.2, 126.4, 120.4 (q, J = 293.1 Hz), 79.8 (dd, J = 59.2, 29.5 Hz), 71.1, 70.6, 70.5, 70.4, 69.4, 69.3, 69.1, 69.0, 49.8, 45.3. ¹⁹F NMR (376 MHz, CDCl₃): δ –73.54. HRMS (MAIDI) m/z: [M + Na]⁺ calcd for C₈₁H₉₉F₅₄N₃NaO₂₇⁺, 2594.5496; found, 2593.5537.

Scaled Synthesis of 40. To a solution of compound 11 (400 mg, 0.50 mmol) in dry DCM (15 mL) at 0 °C were added 1,3,5benzenetricarbonyl trichloride (33.0 mg, 0.12 mmol) and Et_3N (0.05 mL, 0.37 mmol), and the reaction was stirred for 3 h under an Ar atmosphere. The reaction mixture was poured into water and extracted with DCM. The organic layers were washed with saturated NH₄Cl, dried over Na₂SO₄, and concentrated in a vacuum. The product was isolated by column chromatography on silica gel to give 41 as a light yellow oil (292 mg, 92% yield) with MeOH/DCM (1:30) as eluents.

Compound 41 was obtained from compound 19 as a light yellow oil in 86% yield by employing the same synthetic procedures as compound 32. (Compound 41 was purified by silica gel column chromatography (MeOH/DCM = 1:30) as a light yellow oil in 86% yield (135 mg) by employing the same synthetic procedures as compound 32.) ¹H NMR (400 MHz, CDCl₃): δ 7.41 (s, 3H), 4.08 (t, J = 4.9 Hz, 12H), 3.68–3.65 (m, 20H), 3.62–3.51 (m, 145H), 3.45– 3.43 (m, 15H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 170.5, 137.2, 126.3, 120.3 (m, J = 293.9 Hz), 79.7 (dd, J = 59.4, 30.0 Hz), 71.0, 70.59, 70.55, 70.5, 69.3, 69.2, 69.0, 49.7, 45.3. $^{19}{\rm F}$ NMR (376 MHz, CDCl₃): δ –73.47. HRMS (MAIDI) m/z: [M + Na]⁺ calcd for $C_{129}{\rm H}_{195}{\rm F}_{54}{\rm N}_{3}{\rm NaO}_{51}^{+}$, 3651.1787; found, 3651.0635.

Scaled Synthesis of 41. To a solution of compound 11 (400 mg, 0.35 mmol) in dry DCM (15 mL) at 0 °C were added 1,3,5benzenetricarbonyl trichloride (22.9 mg, 0.09 mmol) and Et₃N (0.04 mL, 0.26 mmol), and the reaction was stirred for 3 h under an Ar atmosphere. The reaction mixture was poured into water and extracted with DCM. The organic layers were washed with saturated NH₄Cl, dried over Na₂SO₄, and concentrated in a vacuum. The product was isolated by column chromatography on silica gel to give 41 as a light yellow oil (259 mg, 83% yield) with MeOH/DCM (1:30) as eluents.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.joc.0c00331.

Experimental procedures, compounds characterizations, copies of ${}^{1}\text{H}/{}^{19}\text{F}/{}^{13}\text{C}$ NMR spectra, and mass spectra (PDF)

AUTHOR INFORMATION

Corresponding Authors

- Zhigang Yang Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals and School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, China; ⊙ orcid.org/0000-0002-4857-4850; Email: zgyang@ whu.edu.cn
- Zhong-Xing Jiang Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals and School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, China; orcid.org/0000-0003-2601-4366; Email: zxjiang@whu.edu.cn

Authors

- Jing Zhang Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals and School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, China
- **Yuan Yuan** Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals and School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, China
- Yu Li State Key Laboratory of Magnetic Resonance and Atomic and Molecular Physics, National Center for Magnetic Resonance in Wuhan, Wuhan Institute of Physics and Mathematics, Innovative Academy of Precision Measurement Science and Technology, Chinese Academy of Sciences, Wuhan 430071, China
- Hao Yang Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals and School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, China
- Huaibin Zhang Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals and School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, China
- Shizhen Chen State Key Laboratory of Magnetic Resonance and Atomic and Molecular Physics, National Center for Magnetic Resonance in Wuhan, Wuhan Institute of Physics and Mathematics, Innovative Academy of Precision Measurement Science and Technology, Chinese Academy of Sciences, Wuhan 430071, China

Xin Zhou – State Key Laboratory of Magnetic Resonance and Atomic and Molecular Physics, National Center for Magnetic Resonance in Wuhan, Wuhan Institute of Physics and Mathematics, Innovative Academy of Precision Measurement Science and Technology, Chinese Academy of Sciences, Wuhan 430071, China; orcid.org/0000-0002-5580-7907

Complete contact information is available at: https://pubs.acs.org/10.1021/acs.joc.0c00331

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We gratefully acknowledge financial support from the National Key Research and Development Program of China (2018YFA0704000), the National Natural Science Foundation of China (81625011), and Key Research Program of Frontier Sciences, CAS (QYZDY-SSW-SLH018).

REFERENCES

(1) (a) Harris, J.; Chess, R. Effect of pegylation on pharmaceuticals. *Nat. Rev. Drug Discovery* **2003**, *2*, 214–221. (b) Knop, K.; Hoogenboom, R.; Fischer, D.; Schubert, U. Poly (ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. *Angew. Chem., Int. Ed.* **2010**, *49*, 6288–6596. (c) Parrott, M.; DeSimone, J. Drug delivery: relieving PEGylation. *Nat. Chem.* **2012**, *4*, 13–17. (d) Herzberger, J.; Niederer, K.; Pohlit, H.; Seiwert, J.; Worm, M.; Wurm, F.; Frey, H. Polymerization of ethylene oxide, propylene oxide, and other alkylene oxides: synthesis, novel polymer architectures, and bioconjugation. *Chem. Rev.* **2016**, *116*, 2170–2413. (e) Cui, J.; Björnmalm, M.; Ju, Y.; Caruso, F. Nanoengineering of Poly (ethylene glycol) particles for stealth and targeting. *Langmuir* **2018**, *34*, 10817–10827.

(2) (a) Veronese, F.; Pasut, G. PEGylation, successful approach to drug delivery. *Drug Discovery Today* 2005, 10, 1451–1459. (b) Veronese, F.; Mero, A. The impact of PEGylation on biological therapies. *BioDrugs* 2008, 22, 315–329. (c) Fishburn, C. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. *J. Pharm. Sci.* 2008, 97, 4167–4183. (d) Suk, J.; Xu, Q.; Kim, N.; Hanes, J.; Ensign, L. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. *Adv. Drug Delivery Rev.* 2016, 99, 28–51.

(3) (a) Chapman, A. P.; Antoniw, P.; Spitali, M.; West, S.; Stephens, S.; King, D. J. Therapeutic antibody fragments with prolonged in vivo half-lives. *Nat. Biotechnol.* **1999**, *17*, 780–783. (b) Seely, J. E.; Richey, C. W. Use of ion-exchange chromatography and hydrophobic interaction chromatography in the preparation and recovery of polyethylene glycol-linked proteins. *J. Chromatography A* **2001**, *908*, 235–241. (c) Haag, R.; Kratz, F. Polymer therapeutics: concepts and applications. *Angew. Chem., Int. Ed.* **2006**, *45*, 1198–1215. (d) Fee, C. J.; van Alstine, J. M. PEG-proteins: reaction engineering and separation issues. *Chem. Eng. Sci.* **2006**, *61*, 924–939. (e) Vicent, M. J.; Dieudonne, L.; Carbajo, R. J.; Pineda-Lucena, A. Polymer conjugates as therapeutics: future trends, challenges and opportunities. *Expert Opin. Drug Delivery* **2008**, *5*, 593–614.

(4) (a) Keegstra, E. M. D.; Zwikker, J. W.; Roest, M. R.; Jenneskens, L. W. A highly selective synthesis of monodisperse oligo (ethylene glycols). J. Org. Chem. 1992, 57, 6678–6680. (b) Harada, A.; Li, J.; Kamachi, M. Preparation and characterization of a polyrotaxane consisting of monodisperse poly (ethylene glycol) and.alpha.cyclodextrins. J. Am. Chem. Soc. 1994, 116, 3192–3196. (c) Loiseau, F. A.; Hii, K. K.; Hill, A. M. Multigram synthesis of well-defined extended bifunctional polyethylene glycol (PEG) chains. J. Org. Chem. 2004, 69, 639–647. (d) Ahmed, S.; Tanaka, M. Synthesis of oligo (ethylene glycol) toward 44-mer. J. Org. Chem. 2006, 71, 9884–9886. (e) Niculesco-Duvaz, D.; Getaz, J.; Springer, C. J. Long functionalized

pubs.acs.org/joc

poly(ethylene glycol)s of defined molecular weight: synthesis and application in solid-phase synthesis of conjugates. *Bioconjugate Chem.* **2008**, *19*, 973–981. (f) French, A. C.; Thompson, A. L.; Davis, B. G. High-purity discrete PEG-oligomer crystals allow structural insight. *Angew. Chem., Int. Ed.* **2009**, *48*, 1248–1252. (g) Székely, G.; Schaepertoens, M.; Gaffney, P. R. J.; Livingston, A. G. Iterative synthesis of monodisperse PEG homostars and linear heterobifunctional PEG. *Polym. Chem.* **2014**, *5*, 694–697. (h) Maranski, K.; Andreev, Y. G.; Bruce, P. G. Synthesis of poly (ethylene oxide) approaching monodispersity. *Angew. Chem., Int. Ed.* **2014**, *53*, 6411–6413.

(5) (a) Wan, Z.; Li, Y.; Bo, S.; Gao, M.; Wang, X.; Zeng, K.; Tao, X.; Li, X.; Yang, Z.; Jiang, Z.-X. Amide bond-containing monodisperse polyethylene glycols beyond 10000 Da. Org. Biomol. Chem. 2016, 14, 7912–7919. (b) Yu, Z.; Bo, S.; Wang, H.; Li, Y.; Yang, Z.; Huang, Y.; Jiang, Z.-X. Application of monodisperse PEGs in pharmaceutics: monodisperse polidocanols. Mol. Pharmaceutics 2017, 14, 3473–3479. (c) Deng, T.; Mao, X.; Li, Y.; Bo, S.; Yang, Z.; Jiang, Z.-X. Monodisperse oligoethylene glycols modified propofol prodrugs. Bioorg. Med. Chem. Lett. 2018, 28, 3502–3505. (d) Deng, T.; Mao, X.; Xiao, Y.; Yang, Z.; Zheng, X.; Jiang, Z.-X. Monodisperse oligoethylene glycols modified camptothecin, 10-hydroxycamptothecin and SN38 prodrugs. Bioorg. Med. Chem. Lett. 2019, 29, 581–584. (e) Li, Y.; Wang, X.; Chen, Y.; Yang, Z.; Jiang, Z.-X. Monodisperse polyethylene glycol "brushes" with enhanced lipophilicity, and thermo and plasma stability. Chem. Commun. 2019, 55, 1895–1898.

(6) (a) Sim, S.-L.; He, T.; Tscheliessnig, A.; Mueller, M.; Tan, R. B. H.; Jungbauer, A. Branched polyethylene glycol for protein precipitation. *Biotechnol. Bioeng.* **2012**, *109*, 736–746. (b) Vugmeyster, Y.; Entrican, C. A.; Joyce, A. P.; Lawrence-Henderson, R. F.; Leary, B. A.; Mahoney, C. S.; Patel, H. K.; Raso, S. W.; Olland, S. H.; Hegen, M.; Xu, X. Pharmacokinetic, biodistribution, and biophysical profiles of TNF nanobodies conjugated to linear or branched poly (ethylene glycol). *Bioconjugate Chem.* **2012**, *23*, 1452–1462.

(7) (a) Zhang, H.; Li, X.; Shi, Q.; Li, Y.; Xia, G.; Chen, L.; Yang, Z.; Jiang, Z.-X. Highly efficient synthesis of monodisperse poly (ethylene glycols) and derivatives through macrocyclization of oligo (ethylene glycols). *Angew. Chem., Int. Ed.* **2015**, *54*, 3763–3770. (b) Xia, G.; Li, Y.; Yang, Z.; Jiang, Z.-X. Development of a scalable process for α amino- ω -methoxyl-dodecaethylene glycol. *Org. Process Res. Dev.* **2015**, *19*, 1769–1773. (c) Lv, X.; Zheng, X.; Yang, Z.; Jiang, Z.-X. One-pot synthesis of monodisperse dual-functionalized polyethylene glycols through macrocyclic sulfates. *Org. Biomol. Chem.* **2018**, *16*, 8537– 8545.

(8) (a) Bo, S.; Song, C.; Li, Y.; Yu, W.; Chen, S.; Zhou, X.; Yang, Z.; Zheng, X.; Jiang, Z.-X. Design and synthesis of fluorinated amphiphile as F-19 MRI/fluorescence dual-imaging agent by tuning the selfassembly. J. Org. Chem. 2015, 80, 6360–6366. (b) Bo, S.; Yuan, Y.; Chen, Y.; Yang, Z.; Chen, S.; Zhou, X.; Jiang, Z.-X. In vivo drug tracking with F-19 MRI at therapeutic dose. Chem. Commun. 2018, 54, 3875–3878. (c) Zhang, Y.; Bo, S.; Feng, T.; Qin, X.; Wan, Y.; Jiang, S.; Li, C.; Lin, J.; Wang, T.; Zhou, X.; Jiang, Z.-X.; Huang, P. A versatile theranostic nanoemulsion for architecture-dependent multimodal imaging and dually augmented photodynamic therapy. Adv. Mater. 2019, 31, 1806444. (d) Zhu, J.; Xiao, Y.; Zhang, H.; Li, Y.; Yuan, Y.; Yang, Z.; Chen, S.; Zheng, X.; Zhou, X.; Jiang, Z.-X. Peptidic monodisperse PEG "combs" with fine-tunable LCST and multiple imaging modalities. Biomacromolecules 2019, 20, 1281–1287.

(9) (a) Lange, M.; Pettersen, A. L.; Undheim, K. Synthesis of secondary amines by reductive dimerization of azides. *Tetrahedron* **1998**, *54*, 5745–5752. (b) An, I.-H.; Seong, H.-R.; Ahn, K. H. Reductive dimerization of azides to secondary amines under hydrogenation conditions. *Bull. Korean Chem. Soc.* **2004**, *35*, 420–421.

(10) Ursuegui, S.; Schneider, J. P.; Imbs, C.; Lauvoisard, F.; Dudek, M.; Mosser, M.; Wagner, A. Expedient synthesis of trifunctional oligoethyleneglycol-amine linkers and their use in the preparation of PEG-based branched platforms. *Org. Biomol. Chem.* **2018**, *16* (44), 8579–8584.

(11) (a) Wan, Z.; Li, Y.; Bo, S.; Gao, M.; Wang, X.; Zeng, K.; Tao, X.; Li, X.; Yang, Z.; Jiang, Z. X. Amide bond-containing monodisperse polyethylene glycols beyond 10 000 Da. Org. Biomol. Chem. 2016, 14 (33), 7912–9. (b) Mattarei, A.; Azzolini, M.; Zoratti, M.; Biasutto, L.; Paradisi, C. N-Monosubstituted Methoxy-oligo(ethylene glycol) Carbamate Ester Prodrugs of Resveratrol. Molecules 2015, 20 (9), 16085-102. (c) Pandey, B. K.; Smith, M. S.; Torgerson, C.; Lawrence, P. B.; Matthews, S. S.; Watkins, E.; Groves, M. L.; Prigozhin, M. B.; Price, J. L. Impact of site-specific PEGylation on the conformational stability and folding rate of the Pin WW domain depends strongly on PEG oligomer length. Bioconjugate Chem. 2013, 24 (5), 796-802. (d) Jiang, Z. X.; Feng, Y.; Yu, Y. B. Fluorinated paramagnetic chelates as potential multi-chromic 19F tracer agents. Chem. Commun. 2011, 47 (25), 7233-5. (e) Yue, X.; Wang, Z.; Zhu, L.; Wang, Y.; Qian, C.; Ma, Y.; Kiesewetter, D. O.; Niu, G.; Chen, X. Novel ¹⁹F activatable probe for the detection of matrix metalloprotease-2 activity by MRI/MRS. Mol. Pharmaceutics 2014, 11 (11), 4208-17.